Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy

Intern Med. 2013;52(1):89-95. doi: 10.2169/internalmedicine.52.8622. Epub 2013 Jan 1.

Abstract

Glucocorticoid-induced hyperglycemia is common in patients with or without known diabetes mellitus. Exenatide, a glucagon-like peptide-1 receptor agonist, improves glycemic control without causing weight gain or hypoglycemia and is currently widely used in patients with type 2 diabetes mellitus. We herein report four cases of patients with type 2 diabetes with worsened glycemic control due to glucocorticoids who were successfully treated with exenatide administration.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Glucose / analysis
  • Blood Glucose / drug effects*
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Exenatide
  • Female
  • Follow-Up Studies
  • Glucocorticoids / adverse effects*
  • Glucocorticoids / therapeutic use
  • Humans
  • Hyperglycemia / chemically induced*
  • Hyperglycemia / drug therapy
  • Hyperglycemia / physiopathology
  • Hypoglycemic Agents / therapeutic use*
  • Injections, Subcutaneous
  • Insulin / therapeutic use
  • Male
  • Middle Aged
  • Peptides / therapeutic use*
  • Risk Assessment
  • Sampling Studies
  • Treatment Outcome
  • Venoms / therapeutic use*

Substances

  • Blood Glucose
  • Glucocorticoids
  • Hypoglycemic Agents
  • Insulin
  • Peptides
  • Venoms
  • Exenatide